Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lifted by Summit Trail Advisors LLC

Summit Trail Advisors LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,390 shares of the biopharmaceutical company’s stock after acquiring an additional 133 shares during the quarter. Summit Trail Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,461,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Quent Capital LLC boosted its position in shares of Regeneron Pharmaceuticals by 5.1% in the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 19 shares during the period. CreativeOne Wealth LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $200,000. Gamco Investors INC. ET AL acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $230,000. Gabelli Funds LLC grew its stake in Regeneron Pharmaceuticals by 3.0% during the 1st quarter. Gabelli Funds LLC now owns 1,859 shares of the biopharmaceutical company’s stock valued at $1,789,000 after acquiring an additional 54 shares in the last quarter. Finally, Kennedy Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $5,210,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.9 %

REGN stock opened at $738.00 on Monday. The stock has a market capitalization of $81.10 billion, a price-to-earnings ratio of 18.26, a price-to-earnings-growth ratio of 2.84 and a beta of 0.15. The company has a 50-day moving average of $945.07 and a two-hundred day moving average of $1,027.53. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Finally, Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.55.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.